International Assets Investment Management LLC Buys New Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

International Assets Investment Management LLC bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the fourth quarter, HoldingsChannel.com reports. The fund bought 21,800 shares of the company’s stock, valued at approximately $715,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Intellia Therapeutics by 7.3% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,651 shares of the company’s stock valued at $210,000 after buying an additional 451 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Intellia Therapeutics by 1.8% during the 3rd quarter. Victory Capital Management Inc. now owns 27,316 shares of the company’s stock worth $864,000 after purchasing an additional 470 shares during the last quarter. Interchange Capital Partners LLC increased its position in shares of Intellia Therapeutics by 6.3% during the 4th quarter. Interchange Capital Partners LLC now owns 10,239 shares of the company’s stock worth $311,000 after purchasing an additional 605 shares during the last quarter. Blue Trust Inc. acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth approximately $26,000. Finally, Jennison Associates LLC increased its position in shares of Intellia Therapeutics by 4.8% during the 3rd quarter. Jennison Associates LLC now owns 18,899 shares of the company’s stock worth $598,000 after purchasing an additional 871 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on NTLA shares. Wedbush reaffirmed a “neutral” rating and set a $29.00 price target on shares of Intellia Therapeutics in a research report on Tuesday. The Goldman Sachs Group lowered Intellia Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $136.00 to $32.00 in a research report on Friday, February 23rd. Wolfe Research started coverage on Intellia Therapeutics in a research report on Thursday, February 15th. They set a “peer perform” rating on the stock. Finally, Canaccord Genuity Group boosted their price target on Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $67.00.

Insider Activity at Intellia Therapeutics

In related news, EVP James Basta sold 2,297 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $32.99, for a total value of $75,778.03. Following the completion of the sale, the executive vice president now directly owns 81,571 shares in the company, valued at approximately $2,691,027.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.00% of the stock is currently owned by corporate insiders.

Intellia Therapeutics Trading Down 1.7 %

NTLA stock opened at $21.17 on Thursday. The business’s 50 day simple moving average is $26.81 and its 200 day simple moving average is $27.68. The firm has a market capitalization of $2.04 billion, a PE ratio of -3.91 and a beta of 1.77. Intellia Therapeutics, Inc. has a 1-year low of $20.78 and a 1-year high of $47.48.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.01. The business had revenue of ($1.92) million during the quarter, compared to the consensus estimate of $15.10 million. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. During the same period in the previous year, the company posted ($1.40) EPS. As a group, sell-side analysts predict that Intellia Therapeutics, Inc. will post -5.58 EPS for the current fiscal year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.